UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2004
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 000-33001
NATUS MEDICAL INCORPORATED
(Exact name of registrant as specified in its charter)
| Delaware | 77-0154833 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
1501 Industrial Road, San Carlos, CA 94070
(Address of principal executive offices) (Zip Code)
(650) 802-0400
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
The number of issued and outstanding shares of the registrants Common Stock, $0.001 par value, as of August 9, 2004, was 17,059,561.
NATUS MEDICAL INCORPORATED
| Page No. | ||||
| PART I. |
3 | |||
| Item 1. |
3 | |||
| Condensed Consolidated Balance Sheets as of June 30, 2004 (unaudited) and December 31, 2003 |
3 | |||
| 4 | ||||
| 5 | ||||
| 6 | ||||
| Item 2. |
Managements Discussion and Analysis of Financial Condition and Results of Operations |
11 | ||
| Item 3. |
30 | |||
| Item 4. |
31 | |||
| PART II. |
32 | |||
| Item 2. |
32 | |||
| Item 4. |
32 | |||
| Item 6. |
32 | |||
| 33 | ||||
2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
| June 30, 2004 |
December 31, 2003(1) |
|||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 5,897 | $ | 9,435 | ||||
| Short-term investments |
32,744 | 28,200 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $421 and $395 |
4,466 | 5,682 | ||||||
| Inventories |
3,956 | 5,263 | ||||||
| Prepaid expenses and other current assets |
449 | 528 | ||||||
| Total current assets |
47,512 | 49,108 | ||||||
| Property and equipment, net |
2,355 | 2,668 | ||||||
| Long-term investment |
| 341 | ||||||
| Deposits and other assets |
47 | 111 | ||||||
| Intangible assets |
3,448 | 3,594 | ||||||
| Goodwill |
1,194 | 1,198 | ||||||
| Total assets |
$ | 54,556 | $ | 57,020 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Liabilities: |
||||||||
| Accounts payable |
$ | 1,596 | $ | 1,659 | ||||
| Accrued liabilities |
3,503 | 2,229 | ||||||
| Deferred revenue |
312 | 500 | ||||||
| Total current liabilities |
5,411 | 4,388 | ||||||
| Commitments and contingencies |
| | ||||||
| Stockholders equity: |
||||||||
| Common stock, $0.001 par value, 120,000,000 shares authorized; shares issued and outstanding: 16,752,117 and 16,511,874 |
87,839 | 87,038 | ||||||
| Treasury stock |
(307 | ) | | |||||
| Deferred stock compensation |
(7 | ) | (33 | ) | ||||
| Accumulated deficit |
(38,567 | ) | (34,495 | ) | ||||
| Accumulated other comprehensive income |
187 | 122 | ||||||
| Total stockholders equity |
49,145 | 52,632 | ||||||
| Total liabilities and stockholders equity |
$ | 54,556 | $ | 57,020 | ||||
| (1) | Derived from the consolidated audited financial statements at December 31, 2003. |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2004 |
2003 |
2004 |
2003 |
|||||||||||||
| Revenue |
$ | 8,398 | $ | 7,063 | $ | 16,969 | $ | 13,724 | ||||||||
| Cost of revenue |
3,748 | 2,848 | 7,506 | 5,360 | ||||||||||||
| Gross margin |
4,650 | 4,215 | 9,463 | 8,364 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Marketing and selling |
3,110 | 3,428 | 6,081 | 6,485 | ||||||||||||
| Research and development |
1,072 | 820 | 1,978 | 1,851 | ||||||||||||
| General and administrative |
2,655 | 1,338 | 4,024 | 2,483 | ||||||||||||
| Restructuring |
776 | | 776 | | ||||||||||||
| Total operating expenses |
7,613 | 5,586 | 12,859 | 10,819 | ||||||||||||
| Loss from operations |
(2,963 | ) | (1,371 | ) | (3,396 | ) | (2,455 | ) | ||||||||
| Interest income |
99 | 165 | 196 | 328 | ||||||||||||
| Interest expense |
| (3 | ) | (3 | ) | (6 | ) | |||||||||
| Other income (expense), net |
(177 | ) | 15 | (101 | ) | 22 | ||||||||||
| Loss before provision for income taxes |
(3,041 | ) | (1,194 | ) | (3,304 | ) | (2,111 | ) | ||||||||
| Provision for income taxes |
| 1 | 1 | 1 | ||||||||||||
| Loss from continuing operations |
(3,041 | ) | (1,195 | ) | (3,305 | ) | (2,112 | ) | ||||||||
| Discontinued operations |
(584 | ) | | (767 | ) | | ||||||||||
| Net loss |
$ | (3,625 | ) | $ | (1,195 | ) | $ | (4,072 | ) | $ | (2,112 | ) | ||||
| Basic and diluted net loss per share from continuing operations |
$ | (0.18 | ) | $ | (0.07 | ) | $ | (0.20 | ) | $ | (0.13 | ) | ||||
| Basic and diluted net loss per share |
$ | (0.22 | ) | $ | (0.07 | ) | $ | (0.24 | ) | $ | (0.13 | ) | ||||
| Shares used in computing basic and diluted net loss per share |
16,638 | 16,360 | 16,673 | 16,355 | ||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Six Months Ended June 30, |
||||||||
| 2004 |
2003 |
|||||||
| Operating activities: |
||||||||
| Net loss from continuing operations |
$ | (3,305 | ) | $ | (2,112 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
||||||||
| Depreciation and amortization |
809 | 617 | ||||||
| Stock-based compensation |
378 | 129 | ||||||
| Loss on disposal of assets |
175 | 6 | ||||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts receivable |
1,378 | 1,118 | ||||||
| Inventories |
1,256 | (861 | ) | |||||
| Prepaid expenses and other current assets |
82 | (157 | ) | |||||
| Accounts payable |
(79 | ) | (387 | ) | ||||
| Accrued liabilities and deferred revenue |
1,079 | (6 | ) | |||||
| Net cash provided by (used in) continuing operations |
1,773 | (1,653 | ) | |||||
| Net cash used in discontinued operations |
(406 | ) | | |||||
| Net cash provided by (used in) operating activities |
1,367 | (1,653 | ) | |||||
| Investing activities: |
||||||||
| Acquisition of property and equipment |
(851 | ) | (224 | ) | ||||
| Deposits and other assets |
71 | (3 | ) | |||||
| Purchases of short-term investments |
(31,975 | ) | (28,501 | ) | ||||
| Sales of short-term investments |
27,500 | 25,611 | ||||||
| Purchase of long-term investments |
340 | | ||||||
| Net cash used in continuing operations |
(4,915 | ) | (3,117 | ) | ||||
| Net cash used in discontinued operations |
(129 | ) | | |||||
| Net cash used in investing activities |
(5,044 | ) | (3,117 | ) | ||||
| Financing activities: |
||||||||
| Issuance of common stock |
449 | 356 | ||||||
| Purchase of treasury stock |
(307 | ) | | |||||
| Net cash provided by financing activities |
142 | 356 | ||||||
| Exchange rate effect on cash and cash equivalents |
(3 | ) | (74 | ) | ||||
| Net decrease in cash and cash equivalents |
(3,538 | ) | (4,488 | ) | ||||
| Cash and cash equivalents, beginning of period |
9,435 | 17,768 | ||||||
| Cash and cash equivalents, end of period |
$ | 5,897 | $ | 13,280 | ||||
| Non-cash investing and financing activities: |
||||||||
| Reversal of deferred stock compensation relating to cancellation of stock options |
$ | 20 | $ | | ||||
| Stock compensation relating to accelerated vesting of stock options |
$ | 352 | $ | | ||||